Evaluation of gefitinib for treatment of refractory solid tumors and central nervous system malignancies in pediatric patients

Cancer Investigation

Volumn 24, Issue 3, 2006, Pages 310-317

  Freeman III, Burgess B ^a   Daw, Najat C ^a   Geyer, J Russell ^b   Furman, Wayne L ^a   Stewart, Clinton F ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

Author keywords

Clinical pharmacology; Epidermal growth factor receptor (EGFR); Gefitinib; Pediatrics; ZD1839

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; CAMPTOTHECIN DERIVATIVE; CANERTINIB; DEXAMETHASONE; ELACRIDAR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GEFITINIB; IRINOTECAN; PROTEIN TYROSINE KINASE INHIBITOR;

ANEMIA; AREA UNDER THE CURVE; BRAIN CANCER; CANCER CELL CULTURE; CANCER RADIOTHERAPY; CHILD; CHILDHOOD CANCER; CLINICAL TRIAL; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG MECHANISM; DRY SKIN; EWING SARCOMA; EYE TOXICITY; GASTROINTESTINAL TOXICITY; GLIOMA; HUMAN; INTERSTITIAL LUNG DISEASE; KERATITIS; LUNG TOXICITY; NAUSEA; NEPHROBLASTOMA; NEUROBLASTOMA; OSTEOSARCOMA; PRIORITY JOURNAL; RASH; REVIEW; RHABDOMYOSARCOMA; SKIN TOXICITY; SOLID TUMOR; TUMOR BLEEDING; VOMITING;

ADULT; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CENTRAL NERVOUS SYSTEM NEOPLASMS; CHILD; CLINICAL TRIALS; DRUG RESISTANCE, NEOPLASM; HUMANS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 33646494170     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900600632058     Document Type: Review

References (67)

1. Cohen, S.; Taylor, J.M. Epidermal growth factor: chemical and biological characterization. Recent Prog. Horm. Res. 1974, 30, 533-550.
2. Olayioye, M.A.; Neve, R.M.; Lane, H.A.; Hynes, N.E. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 2000, 19, 3159-3167.
3. Klapper, L.N.; Kirschbaum, M.H.; Sela, M.; Yarden, Y. Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. Adv. Cancer Res. 2000, 77, 25-79.
4. Schlessinger, J.; Ullrich, A. Growth factor signaling by receptor tyrosine kinases. Neuron. 1992, 9, 383-391.
5. Moyer, J.D.; Barbacci, E.G.; Iwata, K.K.; Arnold, L.; Boman, B.; et al. Induction of apoptosis and cell cycle arrest by CP-358, 774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res. 1997, 57, 4838-4848.
6. Rusnak, D.W.; Lackey, K.; Affleck, K.; Wood, E.R.; Alligood, K.J.; Rhodes, N.; et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol. Cancer Ther. 2001, 1, 85-94.
7. Ciardiello, F.; Tortora, G.A. Novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin. Cancer Res. 2001, 7, 2958-2970.
8. Pedersen, M.W.; Meltorn, M.; Damstrup, L.; Poulsen, H.S. The type III epidermal growth factor receptor mutation. Biological significance and potential target for anti-cancer therapy. Ann. Oncol. 2001, 12, 745-760.
9. Haley, J.; Whittle, N.; Bennet, P.; Kinchington, D.; Ullrich, A.; Waterfield, M. The human EGF receptor gene: structure of the 110 Kb locus and identification of sequences regulating its transcription. Oncogene Res. 1987, 1, 375-396.
10. Woodburn, J.R. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol. Ther. 1999, 82, 241-250.
11. Khazaie, K.; Schirrmacher, V.; Lichtner, R.B. EGF receptor in neoplasia and metastasis. Cancer Metastasis Rev. 1993, 12, 255-274.
12. Nishikawa, R.; Sugiyama, T.; Narita, Y.; Furnari, F.; Cavenee, W.K.; Matsutani, M. Immunohistochemical analysis of the mutant epidermal growth factor, DeltaEGFR, in glioblastoma. Brain Tumor Pathol. 2004, 21, 53-56.
13. Barber, T.D.; Vogelstein, B.; Kinzler, K.W.; Velculescu, V.E. Somatic Mutations of EGFR in colorectal cancers and glioblastomas. N. Engl. J. Med. 2004, 351, 2883.
14. Moscatello, D.K.; Holgado-Madruga, M.; Godwin, A.K.; Ramirez, G.; Gunn, G.; et al. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res. 1995, 55, 5536-5539.
15. Okamoto, I.; Kenyon, L.C.; Emlet, D.R.; Mori, T.; Sasaki, J.; et al. Expression of constitutively activated EGFRvIII in non-small cell lung cancer. Cancer Sci. 2003, 94, 50-56.
16. Chen, W.S.; Lazar, C.S.; Poenie, M.; Tsien, R.Y.; Gill, G.N.; et al. Requirement for intrinsic protein tyrosine kinase in the immediate and late actions of the EGF receptor. Nature 1987, 328, 820-823.
17. Tysnes, B.B.; Haugland, H.K.; Bjerkvig, R. Epidermal growth factor and laminin receptors contribute to migratory and invasive properties of gliomas. Invasion Metastasis 1997, 17, 270-280.
18. Al-Obeidi, F.A.; Lam, K.S. Development of inhibitors for protein tyrosine kinases. Oncogene 2000, 19, 5690-5701.
19. Ciardiello, F.; Caputo, R.; Bianco, R.; Damiano, V.; Pomatico, G.; et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin. Cancer Res. 2000, 6, 2053-2063.
20. Wakeling, A.E.; Guy, S.P.; Woodburn, J.R.; Ashton, S.E.; Curry, B.J.; et al. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res. 2002, 62, 5749-5754.
21. Sirotnak, F.M.; Zakowski, M.F.; Miller, V.A.; Scher, H.I.; Kris, M.G. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin. Cancer Res. 2000, 6, 4885-4892.
22. Cohen, M.H.; Williams, G.A.; Sridhara, R.; Chen, G.; McGuinn, W.D., Jr.; et al. United States food and drug administration drug approval summary: gefitinib (ZD1839; Iressa) tablets. Clin. Cancer Res. 2004, 10, 1212-1218.
23. Ranson, M.; Hammond, L.A.; Ferry, D.; Kris, M.; Tullo, A.; et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J. Clin. Oncol. 2002, 20, 2240-2250.
24. Swaisland, H.; Laight, A.; Stafford, L.; Jones, H.; Morris, C.; et al. Pharmacokinetics and tolerability of the orally active selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in healthy volunteers. Clin. Pharmacokinet. 2001, 40, 297-306.
25. Baselga, J.; Rischin, D.; Ranson, M.; Calvert, H.; Raymond, E.; et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J. Clin. Oncol. 2002, 20, 4292-4302.
26. Herbst, R.S.; Maddox, A.M.; Rothenberg, M.L.; Small, E.J.; Rubin, E.H.; et al. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J. Clin. Oncol. 2002, 20, 3815-3825.
27. Inoue, A.; Saijo, Y.; Maemondo, M.; Gomi, K.; Tokue, Y.; et al. Severe acute interstitial pneumonia and gefitinib. Lancet 2003, 361, 137-139.
28. Albanell, J.; Rojo, F.; Averbuch, S.; Feyereislova, A.; Mascara, J.M.; et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J. Clin. Oncol. 2002, 20, 110-124.
29. Lynch, T.J.; Bell, D.W.; Sordella, R.; Gurubhagavatula, S.; Okimoto, R.A.; et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2004, 350, 2129-2139.
30. Paez, J.G.; Janne, P.A.; Lee, J.C.; Tracy, S.; Greulich, H.; et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304, 1497-1500.
31. Pao, W.; Miller, V.; Zakowski, M.; Doherty, J.; Politi, K.; et al. EGF receptor gene mutations are common in lung cancers from "Never Smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. USA 2004, 101, 13306-13311.
32. Cappuzzo, F.; Magrini, E.; Ceresoli, G.L.; Bartolini, S.; Rossi, E.; et al. Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. J. Natl. Cancer Inst. 2004, 96, 1133-1141.
33. Govindan, R.; Kratzke, R.A.; Herndon, J.E..; Niehans, G.A.; Vollmer, R.; et al. Gefitinib in patients with malignant mesothelioma: a phase II study by the cancer and leukemia group B. Clin. Cancer Res. 2005, 11, 2300-2304.
34. Nobuhara, Y.; Onoda, N.; Yamashita, Y.; Yamasaki, M.; Ogisawa, K.; et al. Efficacy of epidermal growth factor receptor-targeted molecular therapy in anaplastic thyroid cancer cell lines. Br. J. Cancer 2005, 92, 1110-1116.
35. Zhu, B.D.; Yuan, S.J.; Zhao, Q.C.; Li, X.; Li, Y.; Lu, Q.Y. Antitumor effect of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, combined with cytotoxic agent on murine hepatocellular carcinoma. World J. Gastroenterol. 2005, 11, 1382-1386.
36. Lockhart, C.; Berlin, J.D. The epidermal growth factor receptor as a target for colorectal cancer therapy. Semin. Oncol. 2005, 32, 52-60.
37. Canil, C.M.; Moore, M.J.; Winquist, E.; Baetz, T.; Pollak, M.; et al. Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the national cancer institute of canada-clinical trials group. J. Clin. Oncol. 2005, 23, 455-460.
38. Maddineni, S.B.; Sangar, V.K.; Hendry, J.H.; Margison, G.P.; Clarke, N.W. Differential radiosensitisation by ZD1839 (Iressa), a highly selective epidermal growth factor receptor tyrosine kinase inhibitor in two related bladder cancer cell lines. Br. J. Cancer 2005, 92, 125-130.
39. Ochs, J.S. Rationale and clinical basis for combining gefitinib (IRESSA, ZD1839) with radiation therapy for solid tumors. Int. J. Radiat. Oncol. Biol. Phys. 2004, 58, 941-949.
40. Stea, B.; Falsey, R.; Kislin, K.; Patel, J.; Glanzberg, H.; et al. Time and dose-dependent radiosensitization of the glioblastoma multiforme U251 cells by the EGF receptor tyrosine kinase inhibitor ZD1839 ('Iressa'). Cancer Lett. 2003, 202, 43-51.
41. Heimberger, A.B.; Learn, C.A.; Archer, G.E.; McLendon, R.E.; Chewning, T.A.; et al. Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosinekinase inhibitor ZD1839 (Iressa). Clin. Cancer Res. 2002, 8, 3496-3502.
42. Rich, J.N.; Reardon, D.A.; Peery, T.; Dowell, J.M.; Quinn, J.A.; et al. Phase II trial of gefitinib in recurrent glioblastoma. J. Clin. Oncol. 2004, 22, 133-142.
43. Meyers, M.B.; Shen, W.P.; Spengler, B.A.; Ciccarone, V.; O'Brien, J.P.; et al. Increased epidermal growth factor receptor in multidrug-resistant human neuroblastoma cells. J. Cell Biochem. 1988, 38, 87-97.
44. Ricci, C.; Polito, L.; Nanni, P.; Landuzzi, L.; Astolfi, A.; et al. HER/ErbB receptors as therapeutic targets of immunotoxins in human rhabdomyosarcoma cells. J. Immunother. 2002, 25, 314-323.
45. Layfield, L.J.; Thompson, J.K.; Dodge, R.K.; Kerns, B.J. Prognostic indicators for neuroblastoma: stage, grade, DNA ploidy, MIB-1-proliferation index, P53, HER-2/Neu and EGFr-a survival study. J. Surg. Oncol. 1995, 59, 21-27.
46. Ghanem, M.A.; Van Der Kwast, T.H.; Den Hollander, J.C.; Sudaryo, M.K.; Mathoera, R.B.; et al. Expression and prognostic value of epidermal growth factor receptor, transforming growth factor-alpha, and C-Erb B-2 in nephroblastoma. Cancer 2001, 92, 3120-3129.
47. Hughes, D.P.; Thomas, D.G.; Giordano, T.J.; Baker, L.H.; McDonagh, K.T. Cell surface expression of epidermal growth factor receptor and Her-2 with nuclear expression of Her-4 in primary osteosarcoma. Cancer Res. 2004, 64, 2047-2053.
48. Bredel, M.; Pollack, I.F.; Hamilton, R.L.; James, C.D. Epidermal growth factor receptor expression and gene amplification in high-grade non-brainstem gliomas of childhood. Clin. Cancer Res. 1999, 5, 1786-1792.
49. Daw, N.C.; Furman, W.L.; Stewart, C.F.; Iacono, L.C.; Krailo, M.; et al. Phase I and pharmacokinetic study of gefitinib in children with refractory solid tumors: a children's oncology group study. J. Clin. Oncol. 2005, 23, 6172-6180.
50. Therasse, P.; Arbuck, S.G.; Eisenhauer, E.A.; Wanders, J.; Kaplan, R.S.; et al. New guidelines to evaluate the response to treatment in solid tumors, european organization for research and treatment of cancer, national cancer institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 2000, 92, 205-216.
51. Stewart, C.F.; Leggas, M.; Schuetz, J.D.; Panetta, J.C.; Cheshire, P.J.; et al. Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice. Cancer Res. 2004, 64, 7491-7499.
52. Pollack, I.F. Brain tumors in children. N. Eng. J. Med. 1994, 331, 1500-1507.
53. Jennings, M.T.; Freeman, M.L.; Murray, M.J. Strategies in the treatment of diffuse pontine gliomas: the therapeutic role of hyperfractionated radiotherapy and chemotherapy. J. Neurooncol. 1996, 28, 207-222.
54. Packer, R.J.; Boyett, J.M.; Zimmerman, R.A.; Rorke, L.B.; Kaplan, A.M.; et al. Hyperfractionated radiation therapy (72 Gy) for children with brain stem gliomas. a childrens cancer group phase I/II trial. Cancer 1993, 72, 1414-1421.
55. Pollack, I.F.; Bredel, M.; Erff, M. Application of signal transduction inhibition as a therapeutic strategy for central nervous system tumors. Pediatr. Neurosurg. 1998, 29, 228-244.
56. Aaronson, S.A. Growth factors and cancer. Science 1991, 254, 1146-1153.
57. Cheng, Y.; Ng, H.K.; Zhang, S.F.; Ding, M.; Pang, J.C.; et al. Genetic alterations in pediatric high-grade astrocytomas. Hum. Pathol. 1999, 30, 1284-1290.
58. Bredel, M.; Pollack, I.F.; Hamilton, R.L.; James, C.D. Epidermal growth factor receptor expression and gene amplification in high-grade non-brainstem gliomas of childhood. Clin. Cancer Res. 1999, 5, 1786-1792.
59. Woods-Ignatoski, K.; Rao, G.; Ethier, S. A small molecule, erbB kinase inhibitor blocks growth and invasion of human breast cancer cells and sensitizes them to ionizing radiation. Proc. Am. Assoc. Cancer. Res. 1999.
60. O'Rourke, D.M.; Kao, G.D.; Singh, N.; Park, B.W.; Muschel, R.J.; et al. Conversion of a radioresistant phenotype to a more sensitive one by disabling ErbB receptor signaling in human cancer cells. Proc. Natl. Acad. Sci. USA 1998, 95, 10842-10847.
61. Erlichman, C.; Boerner, S.A.; Hallgren, C.G.; Spieker, R.; Wang, X.Y.; et al. The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux. Cancer Res. 2001, 61, 739-748.
62. Scheffer, G.L.; Maliepaard, M.; Pijnenborg, A.C.; van Gastelen, M.A.; de Jong, M.C.; et al. Breast cancer resistance protein is localized at the plasma membrane in mitoxantrone- and topotecan-resistant cell lines. Cancer Res. 2000, 60, 2589-2593.
63. Zamber, C.P.; Lamba, J.K.; Yasuda, K.; Farnum, J.; Thummel, K.; et al. Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine. Pharmacogenetics 2003, 13, 19-28.
64. Kruijtzer, C.M.; Beijnen, J.H.; Rosing, H.; Bokkel Huinink, W.W.; Schot, M.; et al. Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GR120918. J. Clin. Oncol. 2002, 20, 2943-2950.
65. Zamboni, W.C.; Houghton, P.J.; Thompson, J.; Cheshire, P.J.; Hanna, S.K.; et al. Altered irinotecan and SN-38 disposition after intravenous and oral administration of irinotecan in mice bearing human neuroblastoma xenografts. Clin. Cancer Res. 1998, 4, 455-462.
66. Crews, K.R.; Furman, W.L.; Panetta, J.C.; Freeman B.B. 3rd; Iacono L.C.; et al. Effect of gefitinib on the bioavailability of oral irinotecan in children with refractory solid tumors. Journal of Clinical Oncology 2004, 22[14S].
67. Furman, W.L.; Crews, K.R.; Billups, C.; Wu, J.; Gajjar, A.J.; Daw, N.C.; Patrick, C.C.; Rodriguez-Galindo, C.; Stewart, C.F.; Dome, J.S.; Panetta, J.C.; Houghton, P.J.; Santana, V.M. Related cefixime allows greater dose escalation of oral irinotecan: a phase I study in pediatric patients with refractory solid tumors. J. Clin. Oncol. 2006, 24, 563-570.